Dr. Uqba Khan
Claim this profileNew York-Presbyterian/Brooklyn Methodist Hospital
Studies Colorectal Cancer
Studies Adenocarcinoma
4 reported clinical trials
15 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
dMMR negative
MSI-H negative
2Adenocarcinoma
dMMR negative
MSI-H negative
Stage IV
Affiliated Hospitals
Clinical Trials Uqba Khan is currently running
Chemotherapy Tailored by ctDNA Status
for Colon Cancer
This trial tests if a blood test for cancer DNA can help decide if colon cancer patients need more treatment after surgery. The test looks for cancer DNA in the blood to predict if the cancer might come back and to guide further treatment.
Recruiting1 award Phase 2 & 3
Ablative Therapy + Systemic Therapy
for Colorectal Cancer
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means that the intention of the local treatment is to eliminate the cancer at that metastatic site. The ablative local therapy will consist of very focused, intensive radiotherapy called stereotactic ablative radiotherapy (SABR) with or without surgical resection and/or microwave ablation, which is a procedure where a needle is temporarily inserted in the tumor and heat is used to destroy the cancer cells. SABR, surgical resection, and microwave ablation have been tested for safety, but it is not scientifically proven that the addition of these treatments are beneficial for your stage of cancer. The addition of ablative local therapy to all known metastatic sites to the usual approach of systemic therapy could shrink or remove the tumor(s) or prevent the tumor(s) from returning.
Recruiting2 awards Phase 3
More about Uqba Khan
Clinical Trial Related4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Uqba Khan has experience with
- Irinotecan
- Leucovorin Calcium
- Fluorouracil
- Irinotecan Hydrochloride
- Bevacizumab
- Cholecalciferol
Breakdown of trials Uqba Khan has run
Colorectal Cancer
Rectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Uqba Khan specialize in?
Uqba Khan focuses on Colorectal Cancer and Adenocarcinoma. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are dMMR negative.
Is Uqba Khan currently recruiting for clinical trials?
Yes, Uqba Khan is currently recruiting for 3 clinical trials in Brooklyn New York. If you're interested in participating, you should apply.
Are there any treatments that Uqba Khan has studied deeply?
Yes, Uqba Khan has studied treatments such as Irinotecan, Leucovorin Calcium, Fluorouracil.
What is the best way to schedule an appointment with Uqba Khan?
Apply for one of the trials that Uqba Khan is conducting.
What is the office address of Uqba Khan?
The office of Uqba Khan is located at: New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York 11215 United States. This is the address for their practice at the New York-Presbyterian/Brooklyn Methodist Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.